TTK

Across TCGA pan-cancer cohorts, TTK Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TTK data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TTK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LUSC, and COAD are the cancer types where TTK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.136	0.806	<.001	27	view →
LUSC	OS	Median	III,IV	0.108	0.691	<.001	24	view →
COAD	DFS	Median	All	0.154	0.572	.002	13	view →
CESC	OS	Median	III,IV	0.185	0.667	.009	12	view →
BLCA	DFS	Median	All	0.247	0.627	.022	6	view →
SKCM	OS	Median	III,IV	0.312	0.707	.025	6	view →
UCEC	DFS	Median	All	0.760	0.635	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TTK–KIRC (OS)

Open the KIRC breakdown →